Last $17.11 USD
Change Today +0.105 / 0.62%
Volume 181.8K
FLML On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael S. Anderson

Chief Executive Officer and Director, Flamel Technologies SA
AgeTotal Calculated CompensationThis person is connected to 11 board members in 1 different organizations across 1 different industries.

See Board Relationships
----

Background*

Mr. Michael S. Anderson, also known as Mike, has been the Chief Executive Officer at Flamel Technologies SA since March 13, 2012. Mr. Anderson served as Chief Executive Officer at Eclat Pharmaceuticals. He has been Director of Flamel Technologies SA since June 2012.

Corporate Headquarters*

Parc Club du Moulin à Vent
Vénissieux, Rhône-Alpes 69693

France

Phone: 33 472 78 34 34
Fax: 33 472 78 34 35

Board Members Memberships*

2012-Present
Chief Executive Officer and Director

Education*

There is no Education data available.

Other Affiliations*

There is no Company Affiliations data available.

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLML:US $17.11 USD +0.105

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ronald W. Barrett Ph.D.Co-Founder, Chief Executive Officer and Director
Xenoport, Inc.
$500.0K
Judith Greciet Ph.D., PharmacyChief Executive Officer, Director and Member of Corporate Development Committee
Onxeo SA
€276.9K
Peter William Grant Chief Executive Officer and Executive Director
Skyepharma PLC
567.0K GBP
Mark A. Sirgo Pharm.D.Chief Executive Officer, President, Chief Scientific Officer, Executive Director and Member of Executive Subcommittee
BioDelivery Sciences International, Inc.
$739.3K
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLAMEL TECHNOLOGIES-SP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.